Evaluate Pharma

Which signal will shape pharma & biotech through 2032? $2 trillion+ market. $500B in sales at risk from patent expiry. Daniel Chancellor and Melanie Senior walk through the data — drugs, therapy areas, pipeline, and the rise of China. Watch on demand. vist.ly/5d5qj

What's next for pharma growth? The Evaluate World Preview 2026 looks at key drivers and emerging risks, from patent cliffs to China's rising influence in drug development. InVivo has the story. (Subscription may be required.) vist.ly/5ctqy. insights.citeline.com/in-vivo/global…

Which signal will shape pharma and biotech by 2032? With $2 trillion+ in the drug market and over $500 billion at risk from generics, explore the trends and forecasts influencing the future in Evaluate World Preview 2026.

Over $500bn in prescription drug sales face generic competition by 2032. Which companies are most exposed, and what are they doing about it? Find out in the Evaluate World Preview 2026: vist.ly/5cj9w

In 2032, the top 10 pharma companies show familiar faces but widening gaps. @EliLillyandCo leads with $137B in annual sales (12.3% CAGR), while @abbvie follows at $86B. The gap between first and third is substantial and growing. Download the full report: vist.ly/5ch88

By 2032, global pharma sales will reach $2 trillion, with five drugs each exceeding $20 billion. The top twenty drugs will represent nearly 20% of total sales, and tirzepatide alone will generate over $70 billion. Download the full 2032 forecast report.

Standardized forecasting = stronger decisions. One leading pharma company worked with Evaluate to build a tailored training program that unified global teams and set best practices for the future. Download the case study. vist.ly/5cbef

The biggest drug ever. A $2 trillion market. And $500 billion in sales are at risk from patent expiry by 2032. World Preview 2026 has the data. But the bigger question is what the industry does with it. Download the full report: vist.ly/5c6w6

Global pharma sales are projected to top $2T by 2032. Scrip explores the latest Evaluate World Preview 2026 findings and the trends powering industry growth. (Subscription may be required.) vist.ly/5b2wj. insights.citeline.com/scrip/market-i…

Norstella is the AI company for biopharma's highest-stakes decisions. Our brands — Citeline, Evaluate, MMIT, Panalgo, Skipta, and The Dedham Group — turn data and insights into actionable AI, always with the patient at the center. Follow @NorstellaCo, Evaluate's parent company.

Assess market needs, prioritize drugs, and connect patients to trials with Norstella. We guide pharma through development using advanced data and machine learning. Follow @NorstellaCo, our parent company, for updates on trials and market dynamics.

Breakthrough drugs take years to reach patients. At Norstella, we speed up this process by guiding teams through the complexities of drug development. Evaluate connects commercial forecasting to clinical and access intelligence. Follow @NorstellaCo for a full lifecycle view.

Data isn't the problem for life sciences companies—it's integration. Evaluate is part of Norstella, uniting forecasting, clinical, regulatory, payer, and commercial intelligence. Discover how commercial intelligence connects to clinical and access data by following @NorstellaCo.

For biotech and pharma companies, the challenge isn't a lack of opportunity; it's navigating it well. Paul Verdin has spent over a decade helping companies do exactly that. Discover what pressures are shaping the industry right now. Read the full Q&A → vist.ly/5bwqf

Different teams. Different forecasting knowledge. Different decisions. One leading pharma company partnered with Evaluate to change that. See how. vist.ly/5bthn

Lilly is forecast to hit $137bn in annual drug sales by 2032. Download the Evaluate World Preview 2026 to see who's pulling ahead and why obesity and autoimmune are doing most of the heavy lifting. Download it here: vist.ly/5bshu

Better accuracy. Stronger collaboration. Deeper market insights. Evaluate's connected forecasting solutions support smarter decisions at every stage of the asset lifecycle. vist.ly/5bjfb

China's share of biotech licensing deal value is projected to exceed two-thirds in 2026, up from less than 5% five years ago, according to the Evaluate World Preview 2026. Read more via @FiercePharma. vist.ly/5bifv. fiercepharma.com/pharma/big-obe…

In 2032, the top 10 pharma companies show familiar faces but widening gaps. @EliLillyandCo leads with $137B in annual sales (12.3% CAGR), while @abbvie follows at $86B. The gap between first and third is substantial and growing. Download the full report: vist.ly/5bajf

Better forecasting starts with the right conversation. No sales pitch. Just Evaluate's experts and 30 minutes to explore whether your process is as strong as it could be. Book your spot when you're ready. vist.ly/5b532